Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted

被引:69
|
作者
Yamanaka, H [1 ]
Nakajima, M [1 ]
Nishimura, K [1 ]
Yoshida, R [1 ]
Fukami, T [1 ]
Katoh, M [1 ]
Yokoi, T [1 ]
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan
关键词
nicotine; LC-MS/MS; CYP2A6; poor metabolizer;
D O I
10.1016/j.ejps.2004.04.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Generally, 70-80% of absorbed nicotine is mainly metabolized to cotinine by cytochrome P450 (CYP) 2A6. There is genetic polymorphism in the human CYP2A6 gene. Among several mutated alleles, CYP2A6*4 allele is a whole deleted type. The purpose of the present study was to clarify the metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for nicotine and its nine metabolites. Excretion levels of nicotine and its metabolites in 24 h accumulated urine after the chewing of one piece of nicotine gum were evaluated in five Japanese subjects whose CYP2A6 genotype was determined. In three subjects with CYP2A6*1A/CYP2A6*1A, CYP2A6*1A/CYP2A6*1B, and CYP2A6*1A/CYP2A6*4 (group I), nicotine was mainly excreted as cotinine, trans-3'-hydroxycotinine, and their glucuronide (approximately 60%). In contrast, in two subjects with CYP2A6*4/CYP2A6*4 (group II), trace levels of cotinine, cotinine N-glucuronide, and cotinine 1'-N-oxide were detected. Trans-3'-hydroxycotinine and its O-glucuronide were not detected. The excretion levels of nicotine itself, nicotine N-glucuronide, and nicotine 1'-N-oxide were higher than those in the other three subjects. The total excretion levels of these three compounds were approximately 95% in group II versus 35% in group I. However, the sum of the excretion levels of nicotine and all metabolites was similar among these five subjects. This is the first report of the metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:419 / 425
页数:7
相关论文
共 50 条
  • [21] Whole deletion of CYP2A6 gene (CYP2A6*4C) and smoking behavior
    Iwahashi, K
    Waga, C
    Takimoto, T
    NEUROPSYCHOBIOLOGY, 2004, 49 (02) : 101 - 104
  • [22] Artemisinin increases CYP2A6 activity in healthy subjects
    Asimus, S.
    Hai, T. N.
    Huong, N. V.
    Ashton, M.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2007, 12 : 160 - 160
  • [23] Is nicotine-craving linked to genetic variants of CYP2A6?
    Riexinger, A
    Collins, S
    Gaertner, L
    Farger, G
    Batra, A
    NICOTINE & TOBACCO RESEARCH, 2005, 7 (04) : 653 - 653
  • [24] DISTRIBUTION OF POLYMORPHIC VARIANTS OF CYP2A6 AND THEIR INVOLVEMENT IN NICOTINE ADDICTION
    Lopez-Flores, Luis A.
    Perez-Rubio, Gloria
    Falfan-Valencia, Ramces
    EXCLI JOURNAL, 2017, 16 : 174 - 196
  • [25] Effects of whole deletion of CYP2A6 on nicotine metabolism in humans
    Zhang, X
    Ameno, K
    Ameno, S
    Kinoshita, H
    Kubota, T
    Kumihashi, M
    Mostofa, J
    Iwahashi, K
    Ijiri, I
    DRUG AND CHEMICAL TOXICOLOGY, 2002, 25 (02) : 203 - 213
  • [26] In silico development of inhibitors of the nicotine metabolising CYP2A6 enzyme
    Rahnasto, M
    Poso, A
    Raunio, H
    Juvonen, RO
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2004, 197 (03) : 285 - 285
  • [27] Grapefruit juice inhibits CYP2A6 and nicotine metabolism.
    Hukkanen, J
    Benowitz, NL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P75 - P75
  • [28] CYP2A6 genotype and toxicity of nicotine in never smokers.
    Dempsey, DA
    Jacob, P
    Tyndale, RF
    Hoffmann, E
    Benowitz, NL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P4 - P4
  • [29] A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur
    Daigo, S
    Takahashi, Y
    Fujieda, M
    Ariyoshi, N
    Yamazaki, H
    Koizumi, W
    Tanabe, S
    Saigenji, K
    Nagayama, S
    Ikeda, K
    Nishioka, Y
    Kamataki, T
    PHARMACOGENETICS, 2002, 12 (04): : 299 - 306
  • [30] Characterization of a genotype previously designated as CYP2A6 D-type:: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese
    Ariyoshi, N
    Sekine, H
    Saito, K
    Kamataki, T
    PHARMACOGENETICS, 2002, 12 (06): : 501 - 504